Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position


    loading  Checking for direct PDF access through Ovid

Abstract

In the present study we investigated and compared the in vivo analgesia of centrally administered endomorphin-2 and morphiceptin, and their analogs modified in position 3. Two series of analogs were synthesized by introducing unnatural aromatic amino acids in the d configuration: 3-(1-naphthyl)-d-alanine (d-1-Nal), 3-(2-naphthyl)-d-alanine (d-2-Nal), 3-(4-chlorophenyl)-d-alanine (d-ClPhe), 3-(3,4-dichlorophenyl)-d-alanine (d-Cl2Phe). Antinociceptive activity of endomorphin-2, morphiceptin, and their analogs was compared in the mouse hot-plate test, performed after i.c.v. administration of the peptides at a dose of 10 μg/animal. The best results were obtained for two morphiceptin analogs, [d-Phe3]morphiceptin and [d-1-Nal3]morphiceptin, which showed greatly improved analgesic activity, as compared to morphiceptin. In the endomorphin-2 series none of the modifications produced analogs more potent than the parent compound, but [d-1-Nal3]endomorphin-2 was the best analog. Antinociception induced by endomorphin-2 was reversed by concomitant i.c.v. administration of [d-Phe3]endomorphin-2, [d-2-Nal3]endomorphin-2, and [d-2-Nal3]morphiceptin, indicating that these analogs were weak μ-opioid antagonists.

    loading  Loading Related Articles